Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis: From bench to bedside

Mileka Gilbert, Marilynn Punaro

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Blood gene expression profiling has led to major advances in the field of rheumatology over the last few decades. Specifically, DNA microarray technology has been integral in increasing our knowledge of key players in the pathogenesis of some rare pediatric rheumatic diseases. Our group, using microarray analysis, identified the interferon (IFN) gene signature in pediatric systemic lupus erythematosus (SLE) and has published data that suggest high doses of intravenous corticosteroid treatment may have benefit over strictly oral regimens. Additionally, DNA microarray technology led to our discovery that the interleukin (IL)-1 gene signature is associated with systemic juvenile idiopathic arthritis (sJIA) and to the use of IL-1 blockade with anakinra in this disease. We also reported the biologic rationale for use of anakinra early in the disease course. Anakinra is now being used as first-line treatment in sJIA in multiple centers. Herein, we review how information obtained from blood gene expression profiling has changed our clinical practice.

Original languageEnglish (US)
Article number16
JournalPediatric Rheumatology
Volume12
Issue number1
DOIs
StatePublished - May 8 2014

Fingerprint

Interleukin 1 Receptor Antagonist Protein
Juvenile Arthritis
Gene Expression Profiling
Systemic Lupus Erythematosus
Pediatrics
Oligonucleotide Array Sequence Analysis
Interleukin-1
Technology
Rheumatology
Microarray Analysis
Rheumatic Diseases
Interferons
Genes
Adrenal Cortex Hormones

Keywords

  • DNA microarray
  • Gene expression profiling
  • Interferon
  • Interleukin-1
  • Systemic juvenile idiopathic arthritis
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Pediatrics, Perinatology, and Child Health

Cite this

Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis : From bench to bedside. / Gilbert, Mileka; Punaro, Marilynn.

In: Pediatric Rheumatology, Vol. 12, No. 1, 16, 08.05.2014.

Research output: Contribution to journalArticle

@article{e6b34e0c013447e1856705ec12df1136,
title = "Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis: From bench to bedside",
abstract = "Blood gene expression profiling has led to major advances in the field of rheumatology over the last few decades. Specifically, DNA microarray technology has been integral in increasing our knowledge of key players in the pathogenesis of some rare pediatric rheumatic diseases. Our group, using microarray analysis, identified the interferon (IFN) gene signature in pediatric systemic lupus erythematosus (SLE) and has published data that suggest high doses of intravenous corticosteroid treatment may have benefit over strictly oral regimens. Additionally, DNA microarray technology led to our discovery that the interleukin (IL)-1 gene signature is associated with systemic juvenile idiopathic arthritis (sJIA) and to the use of IL-1 blockade with anakinra in this disease. We also reported the biologic rationale for use of anakinra early in the disease course. Anakinra is now being used as first-line treatment in sJIA in multiple centers. Herein, we review how information obtained from blood gene expression profiling has changed our clinical practice.",
keywords = "DNA microarray, Gene expression profiling, Interferon, Interleukin-1, Systemic juvenile idiopathic arthritis, Systemic lupus erythematosus",
author = "Mileka Gilbert and Marilynn Punaro",
year = "2014",
month = "5",
day = "8",
doi = "10.1186/1546-0096-12-16",
language = "English (US)",
volume = "12",
journal = "Pediatric Rheumatology",
issn = "1546-0096",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis

T2 - From bench to bedside

AU - Gilbert, Mileka

AU - Punaro, Marilynn

PY - 2014/5/8

Y1 - 2014/5/8

N2 - Blood gene expression profiling has led to major advances in the field of rheumatology over the last few decades. Specifically, DNA microarray technology has been integral in increasing our knowledge of key players in the pathogenesis of some rare pediatric rheumatic diseases. Our group, using microarray analysis, identified the interferon (IFN) gene signature in pediatric systemic lupus erythematosus (SLE) and has published data that suggest high doses of intravenous corticosteroid treatment may have benefit over strictly oral regimens. Additionally, DNA microarray technology led to our discovery that the interleukin (IL)-1 gene signature is associated with systemic juvenile idiopathic arthritis (sJIA) and to the use of IL-1 blockade with anakinra in this disease. We also reported the biologic rationale for use of anakinra early in the disease course. Anakinra is now being used as first-line treatment in sJIA in multiple centers. Herein, we review how information obtained from blood gene expression profiling has changed our clinical practice.

AB - Blood gene expression profiling has led to major advances in the field of rheumatology over the last few decades. Specifically, DNA microarray technology has been integral in increasing our knowledge of key players in the pathogenesis of some rare pediatric rheumatic diseases. Our group, using microarray analysis, identified the interferon (IFN) gene signature in pediatric systemic lupus erythematosus (SLE) and has published data that suggest high doses of intravenous corticosteroid treatment may have benefit over strictly oral regimens. Additionally, DNA microarray technology led to our discovery that the interleukin (IL)-1 gene signature is associated with systemic juvenile idiopathic arthritis (sJIA) and to the use of IL-1 blockade with anakinra in this disease. We also reported the biologic rationale for use of anakinra early in the disease course. Anakinra is now being used as first-line treatment in sJIA in multiple centers. Herein, we review how information obtained from blood gene expression profiling has changed our clinical practice.

KW - DNA microarray

KW - Gene expression profiling

KW - Interferon

KW - Interleukin-1

KW - Systemic juvenile idiopathic arthritis

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84900817454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900817454&partnerID=8YFLogxK

U2 - 10.1186/1546-0096-12-16

DO - 10.1186/1546-0096-12-16

M3 - Article

C2 - 24839407

AN - SCOPUS:84900817454

VL - 12

JO - Pediatric Rheumatology

JF - Pediatric Rheumatology

SN - 1546-0096

IS - 1

M1 - 16

ER -